<DOC>
	<DOCNO>NCT01555112</DOCNO>
	<brief_summary>The purpose study determine whether improved topical ointment formulation , AS101 , safe effective treatment external genital wart female .</brief_summary>
	<brief_title>Safety Efficacy Study Test Topical AS101 External Genital Warts</brief_title>
	<detailed_description>Human papillomavirus ( HPV ) -induced condyloma acuminata ( CA ) , commonly know anogenital genital wart , among common sexually transmitted disease . There wide variety available treatment genital wart , none consider completely effective . It suggest AS101 work stimulate innate acquire arm immune system . In previous proof-of-concept clinical study AS101 topical cream test HPV wart show cure high percentage . However cream formulation unstable therefore new formulation develop mainly carrier . In study improve AS101 ointment test female patient external genital wart open study ass safety efficacy .</detailed_description>
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Ammonium trichloro ( dioxoethylene-O , O'- ) tellurate</mesh_term>
	<criteria>Women 18 year age good health ; Must sign ethics committee approve informed consent form able adhere study visit protocol requirement ; Women must agree avoid sexual contact ointment skin ; All study participant sexually active must use barrier protection method contraception condom addition another birth control measure oral contraceptive , intrauterine device , spermicide surgical sterilization treatment 60 day completion treatment ; Patients first clinical diagnosis external genital wart , external genitalia include vulva ( labia minora majora ) , inguinal fold , pubic area , perineum , perianal , buttock area ; A minimum one lesion maximum 10 lesion identify study entry , maximum diameter large wart large 10 mm ; Papanicolaou smear must obtain female within 12 month Day 1 negative evidence high grade intraepithelial neoplasia . Women high grade intraepithelial neoplasia cytology eligible subsequent colposcopy biopsy suspicious area negative high grade squamous intraepithelial lesion ( Grade 2 3 ) . Atypia , HPV effect , low grade intraepithelial lesion ( Grade 1 ) acceptable . Participation investigational trial within 30 day prior Day 1 ; Use systemic steroid within 30 day Day 1 ; Previous participation trial investigate AS101 indication . Any prior treatment genital wart prior participation ; Topical systemic immunosuppressive immunomodulatory medication ( include corticosteroid ) within 30 day prior Day 1 , study ; Known history HIV , HBV HCV viral infection . Current active infection herpes genitalis history herpes genitalis infection within last 30 day prior Day 1 ( patient longterm suppressive antiviral therapy eligible ) ; Current and/or recurrent pathologically relevant genital infection genital wart ; Diagnosis highgrade cervical dysplasia ; Internal anogenital , vaginal , urethral cervical wart require treatment ; Chronic acute skin condition might interfere evaluation treatment study drug effect ; Cutaneous surgery , include cryosurgery , genital area within 30 day Day 1 ; Screening laboratory test result complete blood count ( CBC ) , chemistry panel , urine pregnancy test urinalysis obtain screening ( Day 14 Day 0 ) : Must within site laboratory 's define normal reference range , and/or accord Investigator 's decision ; Urine pregnancy test female childbearing potential must negative ; Inadequate renal function : Serum Creatinine &gt; 2.0mg/dL ( &gt; 2.0 ULN ) ; Inadequate liver function : Serum ( total ) Bilirubin &gt; 2 mg/dl ALT and/or AST great two time upper limit reference range . Uncontrolled infection acute severe febrile illness ; Diagnosed uncontrolled autoimmune disease ; Pregnant lactating ; Current drug alcohol abuse may interfere objective study ; Known allergy AS101 component investigational formulation ; Subjects clinically significant medical condition , psychiatric condition laboratory abnormality would , judgment Investigator , interfere subject 's ability participate trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>